- Home
- CRDF
as 11-15-2024 4:00pm EST
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 143.4M | IPO Year: | N/A |
| Target Price: | $9.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $6.42 | Next Earning Date: | 11-07-2024 |
| Revenue: | $688,000 | Revenue Growth: | 49.57% |
| Revenue Growth (this year): | 15% | Revenue Growth (next year): | -41.48% |
Latest Cardiff Oncology Inc. News
CRDF Breaking Stock News: Dive into CRDF Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
10 days ago
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
GlobeNewswire
18 days ago
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Simply Wall St.
24 days ago
3 US Penny Stocks With Market Caps Over $40M
GlobeNewswire
3 months ago
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
GlobeNewswire
4 months ago
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
Simply Wall St.
4 months ago
Companies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In Growth
GlobeNewswire
6 months ago
Cardiff Oncology to Present at the Jefferies Healthcare Conference
Compare CRDF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRDF Cardiff Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.